Teacher Retirement System of Texas boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 18.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 28,159 shares of the biopharmaceutical company's stock after purchasing an additional 4,328 shares during the period. Teacher Retirement System of Texas' holdings in Intra-Cellular Therapies were worth $2,352,000 at the end of the most recent quarter.

• MarketBeat Week in Review – 01/13 - 01/17

A number of other institutional investors have also modified their holdings of ITCI. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies in the third quarter worth about $32,000. GAMMA Investing LLC boosted its position in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth approximately $96,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Intra-Cellular Therapies during the 3rd quarter valued at approximately $97,000. Finally, Quarry LP lifted its stake in shares of Intra-Cellular Therapies by 260.0% in the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after purchasing an additional 1,300 shares during the period. Hedge funds and other institutional investors own 92.33% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ITCI. Mizuho lowered shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and dropped their price target for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Royal Bank of Canada restated a "sector perform" rating and set a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Thursday, March 20th. They issued a "hold" rating for the company. Canaccord Genuity Group lowered Intra-Cellular Therapies from a "buy" rating to a "hold" rating and raised their price objective for the company from $119.00 to $132.00 in a report on Friday, January 31st. Finally, Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Ten research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies presently has an average rating of "Hold" and an average price target of $106.08.

• Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

View Our Latest Stock Analysis on ITCI

Intra-Cellular Therapies Stock Down 0.0 %

Shares of NASDAQ ITCI opened at $131.69 on Thursday. The firm has a 50-day simple moving average of $128.89 and a 200-day simple moving average of $98.82. The stock has a market capitalization of $14.00 billion, a price-to-earnings ratio of -151.37 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 52 week low of $64.09 and a 52 week high of $131.79.

• Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Company Profile

(Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

See Also

• Five stocks we like better than Intra-Cellular Therapies
• Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
• Energy Transfer: Powering Data With Dividends and Diversification
• What is a Death Cross in Stocks?
• Qualcomm Stock Is Coiling for a Breakout
• What is MarketRank™? How to Use it
• Is Alphabet Too Cheap to Ignore After Its Recent Correction?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Intra-Cellular Therapies Right Now?

Before you consider Intra-Cellular Therapies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.

While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here